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Abstract
Tinea pedis is a chronic fungal infection of the feet, very often observed in patients who are
immuno-suppressed or have diabetes mellitus. The practicing allergist may be called upon to treat
this disease for various reasons. Sometimes tinea infection may be mistaken for atopic dermatitis
or allergic eczema. In other patients, tinea pedis may complicate allergy and asthma and may
contribute to refractory atopic disease. Patients with recurrent cellulitis may be referred to the
allergist/immunologist for an immune evaluation and discovered to have tinea pedis as a
predisposing factor. From a molecular standpoint, superficial fungal infections may induce a type2
T helper cell response (Th2) that can aggravate atopy. Th2 cytokines may induce eosinophil
recruitment and immunoglobulin E (IgE) class switching by B cells, thereby leading to exacerbation
of atopic conditions. Three groups of fungal pathogens, referred to as dermatophytes, have been
shown to cause tinea pedis: Trychophyton sp, Epidermophyton sp, and Microsporum sp. The disease
manifests as a pruritic, erythematous, scaly eruption on the foot and depending on its location,
three variants have been described: interdigital type, moccasin type, and vesiculobullous type. Tinea
pedis may be associated with recurrent cellulitis, as the fungal pathogens provide a portal for
bacterial invasion of subcutaneous tissues. In some cases of refractory asthma, treatment of the
associated tinea pedis infection may induce remission in airway disease. Very often, protracted
topical and/or oral antifungal agents are required to treat this often frustrating and morbid disease.
An evaluation for underlying immuno-suppression or diabetes may be indicated in patients with
refractory disease.
Introduction
Dermatophytic infection of the skin can manifest in dif-
ferent anatomical regions of the body and have been
accordingly named. Thus, tinea capitis affects the scalp,
tinea barbae- the face, tinea unguum- the nails, tinea man-
uum- the hands, and tinea cruris- the groin area. Tinea
pedis, also known as athlete's foot, is a chronic fungal
infection of the feet and is the focus of this review. Tinea
pedis is estimated to be the second most common skin
disease in the United States, behind acne [1], and up to
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15% of the population may manifest the disease [2,3].
Tinea pedis presents as pruritic, erythematous, inflamed
regions on the feet that may be located on the sole (vesic-
ular type) or lateral aspects (moccasin type) of the foot
and sometimes between the toes (interdigital type). Three
main genera of fungi may cause tinea pedis, Trichophyton,
Epidermophyton, and Microsporum. Other, nondermat-
ophtye, fungi like Malassezia furfur,  corynebacterium
minutissimum, and Candida species may also cause tinea
pedis but fall outside the scope of this review [4,5]. These
fungi may be spread from soil (geophilic), animals (zoo-
philic), or humans (anthropophilic) as well as through
contact with fomites.
Tinea pedis may present to the practicing allergist/immu-
nologist in several ways. It may be mistaken for plantar
eczema or dermatitis. It may complicate the management
of the atopic patient and fungal pathogens themselves
may aggravate asthma or atopic dermatitis. Occasionally,
a patient may be referred for evaluation of recurrent cellu-
litis resulting from a tinea pedis infection rather than from
immune deficiency. For these reasons, the allergist/immu-
nologist must be prepared to evaluate, diagnose, and treat
tinea pedis. This review will discuss the clinical features of
tinea pedis infection, the pathogens incriminated, and the
current treatment options for patients with this disease.
Pathogens
Three species of fungi, Trichophyton rubrum, Trichophyton
mentagrophytes, and Epidermophyton floccosum are together
responsible for the vast majority of cases of tinea pedis
throughout the world. Of these keratinophilic organisms,
Trichophyton rubrum is the most common pathogen asso-
ciated with chronic tinea pedis, while other fungal patho-
gens have also been associated with the disorder and are
listed in Table 1. The factors affecting the transmission of
these dermatophytic pathogens are dependent on the
source of infection, which is usually either human
(anthropophilic), animal (zoophilic) or soil (geophilic).
The most common anthropophilic dermatophyte infec-
tion seen is T. rubrum. A recent study showed that T.
rubrum accounted for over 76% of all dermatophyte infec-
tions, including tinea pedis [1] and may account for over
2/3 of all tinea pedis infections. The spread of infections
with this pathogen have been attributed to large popula-
tion movements during World War II. Outbreaks of infec-
tion of glabrous skin have been associated with contact
with infected, desquamated skin scales. This may occur in
military camps and in factories.
T. rubrum appears in two forms. The first is typically white
and fluffy in appearance with several aerial hyphae and is
called the "downy form". The granular form of T. rubrum,
however, is flat and has no aerial hyphae [6]. It is easily
confused with T. mentagrophytes which is similar in
appearance and causes a more inflammatory form of tinea
pedis. T. rubrum has several club shaped microconidia
that form along the length of the hyphae [7]. Conidia are
asexual spores that form at the tip of conidiophores; in the
same species, these are either large (macroconidia) or
small (microconidia). T. rubrum is not just common in
tinea pedis but in other tinea infections as well.
Trichophyton mentagrophytes is morphologically and char-
acteristically similar to T. rubrum. Both have a downy or
granular appearance and are sometimes indistinguishable
under the microscope. T. mentagrophytes species can be
pale yellow on the underside while T. rubrum is mostly,
but not always, wine colored on the bottom [6]. T. menta-
grophytes  is zoophilic and affects many animal species
including rodents, cats, dogs, and horses. Microsporum
canis, however, is probably the most prevalent of the zoo-
philic dermatophytes.
Trichophyton tonsurans is another anthropophilic fungus
that causes tinea pedis. T. tonsurans is not a common cause
of tinea pedis but its prevalence is increasing in North
America [6]. Cultures of this fungus have short, septate
hyphae with several microconidia that vary from tear drop
to club shape. Many chlamydoconidia, asexual conidia
produced from the hyphae, may be seen but macroco-
nidia are usually rare. T. tonsurans colonies can range in
color from white to brown with an underside ranging
from yellow to red [7].
Another pathogen known to cause tinea pedis and is
responsible for 5% of tinea pedis infections is Epidermo-
phyton floccosum [6]. E. floccosum is an anthropophilic fun-
gus found worldwide and has been incriminated in
several types of tinea infections. Colonies of this fungus
are flat and grainy and range in color from yellow to
brown. E. floccosum has septate hyphae with club shaped
macroconidia. No microconidia are observed in this spe-
cies, but chlamydoconidia can sometimes be seen in older
colonies [7].
Microsporum canis is a zoophilic fungus contracted from
dogs that is a rarer cause of tinea pedis infections [6]. Col-
onies of M. canis are white with a yellow underside and
fluffy appearance while some remain colorless [7]. Their
hyphae are septate, their microconidia are club shaped,
they have many macroconidia, and their cell wall is usu-
ally thick [7]. Lesions caused by this fungus are usually
more severe and are often characterized by erythema [6].
Clinical syndromes
Depending on the pathogen and anatomical distribution,
tinea pedis may present in a given patient as one of several
syndromes. Typically, three variants are seen and includeClinical and Molecular Allergy 2004, 2 http://www.clinicalmolecularallergy.com/content/2/1/5
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the interdigital (Figure 1), moccasin (Figures 2A and 2B),
and vesicobullous forms (Figure 3) of the disease. Some
patients may present with recurrent cellulitis and aggres-
sive attempts have to be made to identify the presence of
tinea pedis as therapy for this condition can alleviate
recurrences of cellulitis. In other patients, asthma exacer-
bations have been linked to the presence of tinea pedis
and immune/allergic responses to these pathogens. These
clinical syndromes are discussed in greater detail in the
following sections.
Interdigital-type tinea pedis
Interdigital tinea pedis is the most common form and
usually manifests in the interspace of the fourth and fifth
digits and may spread to the underside of the toes (Figure
1) [4,8]. Patients often complain of itching and burning
sensations on the feet accompanied by malodor. There are
generally two types of interdigital tinea pedis. The first is
a scaly, dry type called dermatophytosis simplex. The skin
of the interdigital space is dry with low-grade peeling. This
form is usually asymptomatic except for occasional pruri-
tus. The second type is symptomatic and presents with
wet, macerated interdigital spaces. Dermatophytosis com-
plex, as it is called, may have fissuring of the interspace
along with hyperkeratosis, leukokeratosis, or erosions [9].
Wet conditions along with fungal invasion increases the
incidence of bacterial infection in these patients by
breaching cutaneous integrity. In the case of T. metagro-
phytes, bullae may form. In patients with Human Immu-
nodeficiency Virus (HIV) infection and/or others with
impaired T cell function, extensive spread of tinea lesions
to the dorsum of the foot is seen [10]. The infection may
also become resistant to therapy in some of these patients.
In some cases as described recently, tinea pedis may
mimic bacterial cellulitis due to the inflammatory compo-
nent [11]. This may further lead to complications and skin
maceration and damage. As summarized by Semel and
Golden, tinea pedis was discovered in 20 of 24 episodes
(84%) of cellulitis studied [12]. Common bacterial coin-
fection in descending order of frequency in their study
included beta hemolytic streptococci (85%), Staphylococ-
cus aureus (45%) and enterobacteriaceae (35%). These
authors suggested that cultures of interdigital areas for
fungal pathogens combined with antistreptolysin-O titers
(ASO titers) may provide more useful information in
patients with recurrent cellulitis than other routine studies
[12]. A similar syndrome of recurrent cellulitis with tinea
pedis in patients who have undergone saphenous vein
grafting for coronary artery disease has been described
almost two decades ago [13]. Besides tinea pedis, other
interdigital inflammatory conditions need to be included
in the differential diagnosis and include erythrasma,
impetigo, pitted keratolysis, Candida intertrigo, and Pseu-
domonus aeruginosa interdigital infection [14]. These can
often be differentiated by clinical features, gram stains,
and cultures of aspirated material.
Moccasin-type tinea pedis
The moccasin type is a more severe, prolonged form of
tinea pedis that covers the bottom and lateral aspects of
the foot. Its appearance is that of a slipper or moccasin
covering the foot, hence the name (Figures 2A and 2B). T.
rubrum is most commonly associated with moccasin type
tinea pedis. The skin of the inflamed area in this type of
infection is often scaly and hyperkeratotic with erythema
around the soles and sides of the foot [4,8]. Papules may
also be noted around the demarcation line of erythema
that surrounds the foot. Either foot may be affected, how-
ever bilateral involvement is most often seen [14]. Subun-
gual onychomycosis coexisting with moccasin type
Table 1: Pathogens That Cause Tinea Pedis
1. Trichophyton
a. T. rubrum
b. T. mentagrophytes
c. T. tonsurans
2. Epidermophyton
a. E. floccosum
3. Microsporum
a. M. canis
Interdigital tinea pedis affecting the space between the third  and fourth digits Figure 1
Interdigital tinea pedis affecting the space between the third 
and fourth digits. Tinea infections between the toes are com-
mon due to high moisture content and occlusion and often 
present with itching, burning, and/or malodor. This figure 
shows a man with dry-type tinea pedis in the third inter-
space. (Photograph kindly provided by Dr. Stuart Leicht, 
Division of Dermatology, East Tennessee State University).Clinical and Molecular Allergy 2004, 2 http://www.clinicalmolecularallergy.com/content/2/1/5
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dermatophytosis is most often caused by T. rubrum as
well. The differential diagnosis to be considered here are
psoriasis; dyshidrotic, atopic, or allergic eczematous der-
matitis; pitted keratolysis; and various keratodermas [14].
This form responds to itraconazole and other antifungal
agents.
Vesiculobullous tinea pedis
Vesiculobullous tinea pedis is the third type of dermato-
phyte infection of the feet. Occasionally a pustular variant
may be seen. This type comprises pustules or vesicles on
the instep and adjacent plantar surfaces of the feet and is
less common (Figure 3) [8]. Bacterial infection needs to
be considered in the differential diagnosis and ruled out
by microscopy and/or culture. Fluid filled vesicles are
usually clear but pus usually indicates secondary bacterial
infection, most often with Staphylococcus aureus or group A
Streptococcus. This form of tinea pedis may be associated
with dermatophytid or "ID" reaction [14]. KOH prepara-
tions of the aspirate should be examined for presence of
hyphae. Bullous impetigo, allergic contact dermatitis, dys-
hidrotic eczema, and bullous disease all need to be con-
sidered in the differential diagnosis [14].
Predisposing factors
Over the past decade, many fungi that were once thought
not to infect humans have suddenly emerged as human
pathogens. A number of host factors have contributed to
the growing incidence of these fungi in tinea pedis infec-
tions (Table 2). Due to an increase in immune deficiency
diseases (AIDS) and increased numbers of patients receiv-
ing chemotherapy, steroids, organ transplants, and
parenteral nutrition, the incidence of tinea pedis has
increased [6]. The overall health of the patient is another
important risk factor in developing tinea pedis. Patients
who are obese, elderly, or have systemic problems (diabe-
tes mellitus) are at increased risk [6]. Other local factors
that may contribute infection are trauma, excessive mois-
ture, occlusive clothing, and frequent usage of public
showers and pools. A recent study in Israel showed that
repeated foot washing among school children might lead
to delipidation and pH changes in the stratum corneum
which would favor fungal growth [15].
Complications
Lower extremity cellulitis
Cellulitis is a bacterial infection of the subcutaneous lay-
ers of the skin, which usually stems from a skin lesion or
wound. Common predisposing factors for cellulitis
include trauma, ulceration, venous and lymphatic insuffi-
ciency, and peripheral vascular disease. Tinea pedis infec-
tions, most often interdigital type, may be complicated by
cellulitis and has been discussed in the article earlier. Wet,
occlusive conditions developing in the infected inter-
spaces lead to maceration and fissuring of the skin. This
weakens the natural barrier of the skin and may serve as
Bilateral moccasin type tinea pedis lesions Figure 2
Bilateral moccasin type tinea pedis lesions. Moccasin type 
tinea pedis is a more prolonged form of tinea infection that 
surrounds the sole and lateral aspects of the foot in a slipper 
or moccasin distribution. 2A shows hyperkeratotic skin on 
the medial and bottom portions of the foot. 2B shows moc-
casin type tinea pedis on the lateral portion of the foot.
Vesiculobullous type tinea pedis on the plantar surface of the  feet Figure 3
Vesiculobullous type tinea pedis on the plantar surface of the 
feet. This type of tinea pedis usually causes pustules or vesi-
cles on the instep and plantar surfaces of the feet. Bacterial 
infection should be ruled out by microscopy or culture. (Pho-
tograph kindly provided by Dr. Stuart Leicht, Division of 
Dermatology, East Tennessee State University.)Clinical and Molecular Allergy 2004, 2 http://www.clinicalmolecularallergy.com/content/2/1/5
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an entry point for several kinds of pathogenic bacteria. β-
hemolytic streptococci (group A, B C, F, and G), Staphyl-
coccus aureus, Streptococcus pneumoniae, and gram negative
bacilli have all been associated with cellulitis, with β-
hemolytic streptococci being the most prevalent [16].
Semel and Goldin describe 24 episodes of lower extremity
cellulitis in 22 patients, 20 of which had tinea pedis [12].
Of the 20 patients with athlete's foot, all had gram-posi-
tive bacteria isolated from their ipsilateral interdigital web
space, and 85% (17 of the 20 cases) of these had β-hemo-
lytic streptococci present. β-hemolytic streptococci were
found significantly more often in patients with cellulitis
and tinea pedis than in tinea pedis patients alone (p <
0.01). No β-hemolytic streptococci were isolated from
control patients without tinea pedis or cellulitis. They
conclude, but do not prove, that athlete's foot may be a
common entry point for bacteria that cause cellulitis.
Saphenous venectomy has also been associated with
increased incidence of cellulitis and tinea pedis infection
may be a complicating factor [16,17]. However, the infec-
tion may not arise until many years after surgery. A patient
with recurrent cellulitis may be suspected to have an
underlying immune deficiency and may be referred to the
allergist/immunologist. A thorough examination of the
patient's feet and inter-digital spaces will often reveal evi-
dence of recent or active tinea pedis. Treatment of this
condition could result in amelioration of the cellulitis epi-
sodes. Evaluation for and treatment of any underlying dis-
orders that led to a predisposition to tinea pedis (such as
diabetes mellitus, obesity, hygiene) will also be necessary.
In some patients, gram-negative infection may complicate
tinea pedis. Gram-positive bacteria usually dominate the
interdigital spaces of the feet and upon infection with der-
matophytes, bactericidal products similar to penicillin
may inhibit their growth. This may result in a predomi-
nant growth of gram-negative bacteria like pseudomonas,
proteus, and klebsiella, leading to gram-negative cellulitis
[18]. In such situations, demonstration of fungal elements
may become difficult as excessive gram-negative bacterial
presence may inhibit fungal growth and make it harder to
detect fungal hyphae on KOH preparations. Antifungal
agents released from the gram-negative bacteria may also
contribute to decreased presence of fungus. Hence, cul-
tures of skin scraping may demonstrate gram-negative
bacteria but no fungal pathogens. Aggressive treatment of
the underlying fungal as well as the gram-negative bacte-
rial infection can, however, lead to amelioration of cellu-
litis in these patients.
Tinea unguum (onychomycosis)
Tinea unguium is a fungal infection, usually with a der-
matophyte, on the matrix, plate, or nail bed commonly
associated with tinea pedis. Like tinea pedis infections, T.
rubrum is the major cause of subungual onychomycosis.
Not all thick, brittle, and discolored nails are due to der-
matophyte infections. Onychomycosis accounts for about
one third of fungal skin infections but only about half of
onychomycosis infections are caused by a dermatophyte
[19]. This means a KOH prep or fungal culture should be
done before instating treatment.
Dermatophytid and Majocchi's granuloma
Dermatophytid, also referred to as the "ID" reaction, is an
immunological reaction secondary to tinea pedis along
with other tinea infections. It most often causes vesicular
or pustular eruptions near the site of infection or on the
palms and fingers of the hands [14]. Dermatophytid reac-
tions may be the only sign in asymptomatic tinea pedis
infections. The reaction usually subsides with antifungal
therapy. In some patients with follicular invasion, a
Table 2: Predisposing Risk Factors for Tinea Pedis
A. Host Factors
1. Immunosuppression
a.) Chemotherapy
b.) Immunosuppressive Drugs
c.) Steroids
d.) Organ Transplant
e.) Acquired Immunodeficiency Syndrome (AIDS)
2. Poorly controlled diabetes mellitus
3. Obesity
4. Age
B. Local Factors
1. Trauma
2. Occlusive Clothing
3. Public Showering
4. Moist ConditionsClinical and Molecular Allergy 2004, 2 http://www.clinicalmolecularallergy.com/content/2/1/5
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residual granuloma develops that is sterile. This is referred
to as Majocchi's granuloma and it resolves with time.
Asthma and atopic disease
Case reports of asthma associated with dermatophytic
infections have been described. Ward and coworkers
described "Trichophyton asthma" in 12 adult patients
with chronic rhinitis and asthma who also demonstrated
immediate hypersensitivity to Trichophyton spp [20]. 10
out of the 12 patients also demonstrated positive immedi-
ate broncho-constrictive reactions to extracts of T. ton-
surans. These patients had eosinophilia and chronic
rhinosinusitis in addition to features compatible with
"intrinsic or late onset asthma". Mungan et al. described
coinfection with T. rubrum in patients with chronic
asthma who also had evidence of tinea pedis [21]. The
dominant pathogens were T. rubrum (63.1%) and T. men-
tagrophytes  (35.5%). These investigators suggested that
patients with intrinsic asthma needed to be tested for sen-
sitivity to Trichophyton spp. Other investigators have also
discussed a possible relationship between dermatophytic
infections and asthma [22,23]. Hurliman and Fah
described 2 patients who presented with tinea unguum
caused by T. rubrum but also had underlying asthma,
rhinitis, and eczema [23]. The allergic disease improved
rapidly when the patients were treated with terbinafine
and relapsed rapidly after this therapy was discontinued.
Klein and coworkers described a patient with atopic der-
matitis and concurrent tinea pedis and onychomycosis
[24]. Skin cultures were positive for T. rubrum and atopic
eczema flares improved with the use of antifungal agents
[24]. As reviewed by Leyden, mocassin-type tinea pedis
occurs more often in patients with an atopic background
[25]. Byrld and coworkers found an association between
tinea pedis and risk for vesicular eruption on the hands of
patients [26]. The use of systemic antifungal therapies and
ketoconazole shampoos led to improvement in 5 patients
with atopic dermatitis complicated by dermatophytosis
[27]. Mungan et al. demonstrated that trichophyton
hypersensitivity may also be seen in patients with intrinsic
asthma (nonallergic asthma) suggesting that both allergic
and nonallergic asthma may have components of fungal
sensitivity [21]. The role of Mallasezia (pityrosporium spe-
cies) in atopic eczema has been extensively reviewed by
several investigators [28-31]. Ward and coworkers dem-
onstrated that treatment of 11 patients with late onset
asthma complicated by dermatophytosis with fluconazole
led to improved lung function and symptoms, and
decreased steroid usage [32]. This was also echoed in a
report by Elewski and Schwartz [22]. Mandez and col-
leagues also reported on one patient with urticaria com-
plicating dermatophytosis [33]. Treatment of the fungal
dermatitis led to clearing of the urticaria. This, being an
anecdotal report, requires confirmation in larger studies.
Molecular immunopathogenesis
The relationship between fungal dermatitis and atopic
disease is interesting. In one study, peripheral blood
mononuclear cells from some patients with atopic derma-
titis released interleukin-5 (IL-5) in response to stimula-
tion by fungal antigens [34]. This response appeared to
correlate with severity of facial dermatitis in these
patients. Kanda and colleagues also demonstrated expres-
sion of the Th2 cytokine IL-4 from peripheral blood
mononuclear cells in response to stimulation by
Trichophyton rubrum [35]. Johansson and coworkers
showed that a positive response to patch testing with
Malassezia furfur in atopic dermatitis patients correlated
with a Th2 cytokine response (IL-4, IL-5, and IL-13) in
peripheral blood mononuclear cells [36]. The possible
interactions of dermatophytes with T-cells and triggering
of atopic disease is shown in Figure 4. Activation of cuta-
neous and/or circulating T cells by fungal antigens could
induce a Th2-dominant response leading to elaboration
of IL-4, IL-5, and IL-13. The first two cytokines can lead to
two pivotal effects: synthesis of IgE by B cells and
endothelial activation leading to eosinophil recruitment
by a vascular cell adhesion molecule (VCAM)-very late
activating antigen 4 (VLA-4) adhesion molecule pathway.
Both IgE and eosinophils play a prominent role in atopic
disease. IgE in the presence of antigen can cross-link mast
cells leading to further cytokine, chemokine, and media-
tor production. The other cytokine, IL-5, enhances eosi-
nophil production from the bone marrow, eosinophil
activation, survival, recruitment, and degranulation.
These processes can result in expression of atopic disease,
from rhinitis and asthma to atopic dermatitis.
Diagnosis
Tinea pedis infections are typically easy to distinguish and
diagnose. However, complete identification of the causa-
tive fungi should be established to confirm diagnosis and
ensure proper treatment. Diagnosis of tinea pedis is based
on history and clinical appearance of the feet in addition
to direct microscopy of a potassium hydroxide (KOH)
preparation. Cultures or histological examinations are
rarely required. A Wood's lamp is not usually helpful in
diagnosing tinea pedis but can be used to rule out other
diagnoses like infection with Malassezia furfur [1] or
erythrasma [14]. Malassezia furfur and  Corynebacterium
minutissimum both fluoresce under ultraviolet light while
other common dermatophytes do not. KOH preparations
are simple, inexpensive, efficient, and widely used. The
KOH preparation also has an excellent positive predictive
value. Occasionally, false negative results may be
obtained, especially if treatment has already begun.
To prepare a KOH slide of the suspected fungi, the proce-
dure has to be followed carefully. First of all, skin cells
from the periphery of the affected area are scrapped offClinical and Molecular Allergy 2004, 2 http://www.clinicalmolecularallergy.com/content/2/1/5
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onto a glass microscope slide with a sterile scalpel blade.
One to two drops of 10% KOH solution is dropped onto
the slide and heated gently to dissolve skin cells while
keeping the fungal hyphae intact (Figure 5). Slide prepa-
rations should then be examined under low or medium
power of a microscope. If a vesicle is being examined, it
may be unroofed so the inside material may be examined.
Treatment
Tinea Pedis usually responds to topical antifungal agents
such as ketoconazole, terbinafine, econazole, or cicloprox
creams. In the case of interdigital infection, antifungal
powder preparations may be more effective. Topical treat-
ment may need to be continued for at least 4 weeks and
recurrences are common. For refractory or resilient dis-
ease, oral antifungals may be required. Treatment options
and dosing are explained in greater detail below and are
reviewed in Table 3. Oral treatment with griseofulvin, itra-
conazole, fluconazole, and terbinafine may all be effective
for this disease. Drug resistance, adverse effects of
medications and drug interactions are all major hurdles to
successful completion of therapy. An evaluation for
Activation of cutaneous and/or circulating T cells by fungal antigens could induce a Th2-dominant response leading to elabora- tion of IL-4, IL-13 and IL-5 Figure 4
Activation of cutaneous and/or circulating T cells by fungal antigens could induce a Th2-dominant response leading to elabora-
tion of IL-4, IL-13 and IL-5. The first 2 cytokines can lead to two pivotal effects: Synthesis of IgE by B cells and endothelial acti-
vation leading to eosinophil recruitment by a vascular cell adhesion molecule (VCAM)-very late activating antigen 4 (VLA-4) 
adhesion molecule pathway. Both IgE and eosinophils play a prominent role in atopic disease. IgE in the presence of antigen can 
cross-link mast cells leading to further cytokine, chemokine and mediator production. The other cytokine, IL-5, enhances eosi-
nophil production from the bone marrow, eosinophil activation, survival, recruitment and degranulation. These processes can 
result in expression of atopic disease, from rhinitis and asthma to atopic dermatitis.Clinical and Molecular Allergy 2004, 2 http://www.clinicalmolecularallergy.com/content/2/1/5
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etiologies for immunosupression such as new onset dia-
betes or malignancy may be indicated in selected patients.
Possible drug-drug interactions are listed in Table 4,
adapted from "Oral antifungal drug interactions" by Katz
and Gupta [37].
Non-pharmacological
Non-pharmacological treatment focuses on educating
patients about the predisposing factors, and the chronic
nature of disease. Also, measures that are aimed at elimi-
nating the moisture that provides the environment for
infection and its recurrence should be discussed fully with
the patients. Instructions about wearing open-toed shoes
and avoiding skin maceration are essential.
Pharmacological
Topical treatment
Data has shown that topical antifungal treatment fails to
cure about one-third of patients with tinea pedis [38].
However, most of the relapses were due to poor compli-
ance. So it must be emphasized that the patient should
continue topical treatment at least one week after symp-
toms have resolved. The application area should include
normal skin about 2 cm beyond the affected area. Many
studies have compared the efficacy and rate of relapse
upon applying different topical antifungal agents. None
of them showed 100% superiority of one treatment or
regimen over the other. A comparison study by Suschka et
al. between clotrimazole once daily 1% cream and ketoco-
nazole twice/day 2% cream showed that clotrimazole
once per day is as effective as twice per day ketoconazole
[39]. Another randomized, double-blind parallel group
study compared efficacy and tolerability of topical
terbinafine 1% cream, twice a day for one week, with clot-
rimazole 1% cream, twice a day for 3 weeks, and showed
that terbinafine achieves a cure rate more rapidly than
clotrimazole and in a shorter amount of time [3]. Topical
corticosteroids combined with topical antifungal agents
KOH preparation of fungal hyphae Figure 5
KOH preparation of fungal hyphae. This slide shows the branched hyphae of T. rubrum. Scrapings from the outer edge of a 
tinea lesion should be taken with a sterile scalpel, placed on a slide and KOH applied. KOH dissolves the epithelial cells seen in 
the background and leaves the fungus to be viewed by microscopy.Clinical and Molecular Allergy 2004, 2 http://www.clinicalmolecularallergy.com/content/2/1/5
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(for example, in the form of clotrimazole-betamethasone)
provide rapid symptomatic relief in addition to eradica-
tion of the causative organism. With long-term use of
topical glucocorticosteroids atrophy and steroid-induced
rosacea and striae may occur. These combination agents
are relatively contraindicated in children under12 years of
age [1].
Systemic antifungal therapy
Systemic treatment may be required for patients who have
failed with topical antifungal therapy. It can also be used
as a first line therapy in patients with severe disease like
hyperkeratotic lesions or in patients who are immunosup-
pressed [40]. A list of common oral therapies and their
dosages are listed in Table 3.
Griseofulvin concentrates in the stratum corneum of the
skin and causes mitotic arrest during microtubule spindle
formation in actively growing fungi [41]. Cure is difficult
to achieve and the recurrence rate is high. Blood counts
and serum chemistry including renal and hepatic function
should be checked regularly throughout treatment, as Gri-
seofulvin may have toxic effects on the liver.
The azoles, as a group, include ketoconazole, itracona-
zole, and fluconazole. Doses, indications for usage, and
adverse effects are all readily available in textbooks. Table
4 provides a list of important drug-drug interactions for
this group of medications that may influence treatment
decisions and/or influence patient outcomes. Ketocona-
zole treatment is indicated when griseofulvin therapy has
failed or when the patient cannot tolerate it. Blood counts
Table 3: List of Oral Antifungal Therapies, Their Dosages, and Their Possible Side Effects
DRUG DOSE SIDE EFFECTS
1. Griseofulvin* 375–500 mg qd 3–6 months Nausea, Hepatotoxic, Photosensitivity, Headache, Leukopenia+, 
Neutropenia+
2. Azoles
A. Ketoconazole** 200–400 mg qd 6–8 weeks Hepatotoxic, Hepatitis Idiosyncratic rxn, Nausea, Vomiting, Diarrhea
B. Itraconazole 100 mg qd 2–4 weeks Abdominal pain, Increased transaminases
400 mg qd 1 week
C. Fluconazole 50 mg qd 6 weeks Hepatotoxic+, Anaphylaxis
100 mg qd 8 weeks
150 mg q week 6 weeks
3. Allylamines
A. Terbinafine 125 mg qd 8 weeks Headache, Rash, Cholestatic hepatitis, Blood dyscrasia Steven-
Johnson Syndrome
250 mg qd 2–6 weeks
* Contraindicated in pregnancy ** Contraindicated in nursing women, + Rare side effect
Table 4: List of Possible Drug-Drug Interactions with Oral Antifungal Therapy
1. Griseofulvin:
Aspirin, Oral contraceptives, Phenobarbital, Porfimer, Theophylline, Warfarin
2. Ketoconazole:
Alcohol, Oral hypoglycemics, Phenytoin
3. Itraconazole:
Alfentanil, Alprazolam, Amphotericin B, Agenerase, Antacids, Atorvastatin, Bexarotene, Buspirone, Bussulfan, Carbamazepine, Cilostazol, 
Cimetidine, Cisapride, Citalopram, Clarithromycin, Cyclosporine, Diazepam, Didanosine, Digotoxin, Docetaxel, Dofetilide, Erythromycin, 
Famatidine, Felodipine, Grapefruit juice, Haloperidol, Indinavir, Isoniazid, Lansoprazole, Lovastatin, Methylprednisone, Midazolam, Nevirapine, 
Nifedipine, Omeprazole, Oral hypoglycemics, Phenobarbital, Phenytoin, Pimazide, Quinidine, Ranitidine, Rifabutin, Rifampin, Retonavir, 
Saquinavir, Sildenafil, Simvastatin, Sirolimus, Sodium bicarbonate, Sucralfate, Tacrolimus, Triazolam, Trimetrexate, Verapamil, Vincristine, 
Warfarin
4. Fluconazole:
Amphotericin B, Celecoxib, Cimetidine, Cisapride, Citalopram, Cyclosporine, Defetilide, Felodipine, Glipiside, Glyburide, Hydrochlorothiazide, 
Lovastatin, Midazolam, Oral hypoglycemics, Phenytoin, Pimozide, Prednisone, Quinidine, Rifabutin, Rifampin, Sildenafil, Simvastatin, Sirolimus, 
Tacrolimus, Theophylline, Trizolam, Warfarin, Zidovudine
5. Terbinafine:
Cimetidine, Cyclosporine, Nortriptyline, Rifampin, Terfenadine, Theophylline, WarfarinClinical and Molecular Allergy 2004, 2 http://www.clinicalmolecularallergy.com/content/2/1/5
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and serum chemistry should be monitored more fre-
quently during this therapy. Dosage adjustment may not
be necessary in patients with renal failure. Absorption is
improved by food, so food intake should be encouraged
with the ketoconazole treatment. Due to its structural dif-
ference, itraconazole has greater efficacy and less toxicity
as compared with other azoles. Also its absorption is
enhanced by coadministration with food. No dose adjust-
ment is needed in renal failure. Fluconazole has more
potency, less toxicity, and wider spectrum of action than
earlier azoles. A comparison study by Nozickova et al in
1998 between fluconazole at 50 mg/day for 6 weeks and
fluconazole at 150 mg/week for 6 weeks showed no sig-
nificant difference in cure rates between the two [42]. Flu-
conazole and itroconazole should not be given together
with terfenadine, astemizole, and cisapride in view of the
risk of cardiac arrhythmia.
Another group of drugs classified as allylamines include
terbinafine as a member. These drugs act by destroying the
fungal cell wall at a much earlier stage in its development
than the azoles. Terbinafine may be the most effective
treatment for tinea pedis. However, as a cost-effective
option it is not the first line of therapy. Blood counts,
platelet count, and liver enzymes should be repeated every
4–6 weeks with this therapy. Allylamines must be stopped
if liver enzyme measurement exceeds twice the normal
level.
Conclusions
Tinea pedis is a common dermatophyte infection of the
feet. Classifying the type and causative organism of tinea
pedis is important for proper treatment of the patient. The
easiest way to test for fungal presence is by microscopy of
a KOH preparation, but complete identification of the
organism requires culturing. Tinea pedis infection can
contribute not only to fungal dermatitis but also to flares
of eczema and asthma. Tinea pedis may lead to severe bac-
terial cellulitis. Aggressive treatment of tinea pedis can be
associated with improvements in atopic dermatitis,
asthma and cellulitis in affected individuals.
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